The Study on the Characters of HBV-specific T Cells and Liver Damage Between HBeAg(+) and HBeAg(−) CHB Patients

G. Peng,W. Wu,X. Tan,Z. Sun,Y. Chen,Z. Chen
DOI: https://doi.org/10.1016/j.ijid.2008.05.1246
IF: 12.073
2009-01-01
International Journal of Infectious Diseases
Abstract:Aims: To study the quantity and quality of HBV-specific T cells in chronic hepatitis B (CHB) patients with different HBeAg status, and to investigate the extent of liver damage between HBeAg(+) and HBeAg(−) CHB patients. Methods: A total of 103 CHB patients were selected and divided into two groups according to the HBeAg status. The serum HBV markers, liver damage (necroinflammation gradation) were analyzed. The frequency and Foxp3 expression of CD4+CD25+ regulatory T cells (Treg), the HBV-pentamer(+) T cell frequency and the expression levels of PD-1, CTLA-4 on HBV-specific T cells were measured. HBV antigens specific T-cell responses including cellular proliferation and IFN- γ production, with or without anti-PD-1 mAb and/or anti-CTLA-4 mAb blocking, were also tested in vitro Results: The demographic characters, serum ALT levels, the frequency and Foxp3 expression of Treg were similar between HBeAg(+) and HBeAg(−) patients, and the serum HBV DNA levels were higher in HBeAg(+) patients (P < 0.05). The liver necroinflammation was comparatively severe in HBeAg(−) patients (P = 0.052), while the median percentage of liver cirrhosis was much higher in HBeAg(+) patients (P < 0.05). The difference of HBV-specific T-cell frequency was not significant between HBeAg(+) and HBeAg(−) patients, whereas the expression levels of PD-1 and CTLA-4 on HBV-pentamer(+) T cells were significantly higher in HBeAg(+) patients (P both < 0.05). Combined using of anti-PD-1 and anti-CTLA-4 mAb could significantly increase the cellular proliferation in either HBeAg(+) or HBeAg(−) patients, and markedly enhanced the IFN-γ production in HBeAg(+) patients. Conclusion: The persistency of HBeAg could induce higher expression of PD-1 and CTLA-4 on the HBV-specific T cells, which may associate with the low ability of HBV-specific T-cell responses, high serum HBV DNA levels and high percentage of liver cirrhosis in HBeAg(+) CHB patients.
What problem does this paper attempt to address?